Clinical Trial Update: A Study of MFA-370 in Patients with Metastatic Urothelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating MFA-370 in metastatic urothelial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• MFA-370

Snippet

Sponsor: Ectin Research AB | Conditions: Metastatic Urothelial Cancer | Phase 1, Phase 2 | Status: WITHDRAWN